Home » Stocks » ABIO

ARCA biopharma, Inc. (ABIO)

Stock Price: $4.75 USD 0.30 (6.74%)
Updated Jan 19, 2021 4:00 PM EST - Market closed
Pre-market: $4.66 -0.09 (-1.90%) Jan 20, 7:00 AM
Market Cap 44.28M
Revenue (ttm) n/a
Net Income (ttm) -5.84M
Shares Out 6.04M
EPS (ttm) -2.11
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 19
Last Price $4.75
Previous Close $4.45
Change ($) 0.30
Change (%) 6.74%
Day's Open 4.48
Day's Range 4.43 - 4.80
Day's Volume 902,504
52-Week Range 2.32 - 19.21

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 1 month ago

WESTMINSTER, Colo., Dec. 09, 2020 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), today announced that its 2020 Annual Meeting of Stockholders, scheduled for Thursday, December 10, 20...

Market Watch - 1 month ago

Shares of ARCA Biopharma Inc. gained 5.5% in trading on Monday after the company said it received a Fast-Track designation from the Food and Drug Administration for its mid-stage experimental ...

GlobeNewsWire - 1 month ago

WESTMINSTER, Colo., Nov. 23, 2020 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted...

GlobeNewsWire - 2 months ago

WESTMINSTER, Colo., Nov. 02, 2020 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted...

GlobeNewsWire - 3 months ago

WESTMINSTER, Colo., Oct. 07, 2020 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted...

GlobeNewsWire - 3 months ago

WESTMINSTER, Colo., Oct. 05, 2020 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted...

GlobeNewsWire - 3 months ago

WESTMINSTER, Colo., Sept. 21, 2020 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targe...

GlobeNewsWire - 5 months ago

WESTMINSTER, Colo., Aug. 05, 2020 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically target...

GlobeNewsWire - 7 months ago

WESTMINSTER, Colo., June 03, 2020 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO) a late stage biopharmaceutical company applying a precision medicine approach to developing genetica...

GlobeNewsWire - 7 months ago

WESTMINSTER, Colo., June 01, 2020 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO) a late stage biopharmaceutical company applying a precision medicine approach to developing genetica...

Investors Business Daily - 7 months ago

Shares of Arca Biopharma tripled in value Thursday after the biotech company announced it would develop a coronavirus treatment for patients with abnormal blood clotting. The post Arca Biophar...

Benzinga - 7 months ago

Arca Biopharma Inc (NASDAQ: ABIO) shares are skyrocketing toward their highest level in more than a year following an announcement from the company regarding its plan to develop a COVID-19 tre...

GlobeNewsWire - 7 months ago

WESTMINSTER, Colo., May 28, 2020 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO) today announced a new development program to evaluate AB201 (rNAPc2), a potent, selective inhibitor o...

GlobeNewsWire - 8 months ago

New data provide additional evidence of efficacy for Gencaro compared to active control in a pharmacogenetically-defined HF population at risk for AF recurrence

GlobeNewsWire - 8 months ago

WESTMINSTER, Colo., May 06, 2020 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targete...

GlobeNewsWire - 1 year ago

WESTMINSTER, Colo., Sept. 11, 2019 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targe...

Seeking Alpha - 1 year ago

ARCA biopharma published positive results from its phase 2b GENETIC-AF study using Gencaro to treat patients with genetically-defined heart failure with atrial fibrillation.

CNBC Television - 2 years ago

Pharma CEO defends 400% price hike as moral requirement

The "Squawk Box" news team discusses some of the morning's most provocative headlines.

Other stocks mentioned: JWN

About ABIO

ARCA biopharma operates as a biopharmaceutical company applying a precision medicine approach to developing and commercializing genetically targeted therapies for cardiovascular diseases. Its lead product candidate, Gencaro (bucindolol hydrochloride) is pharmacogenetically-targeted beta-adrenergic receptor antagonist, which is in the development for the treatment of atrial fibrillation in certain patients who also have heart failure (HF). The company also engages in the development of AB171, a thiol-substituted isosorbide mononitrate for the tr... [Read more...]

Industry
Biotechnology
CEO
Michael Bristow
Employees
13
Stock Exchange
NASDAQ
Ticker Symbol
ABIO
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

The average 12-month stock price forecast for ARCA biopharma is 7.00, which is an increase of 47.37% from the latest price.

Price Target
$7.00
(47.37% upside)